INVIVYD, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
INVIVYD, INC. (IVVD) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $804.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $459.00K, a 30.40% increase year-over-year.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $345.00K, a 20.14% decline year-over-year.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $286.00K, a 33.80% decline year-over-year.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $282.00K, a 33.96% decline year-over-year.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.35M, a 17.91% decline from fiscal 2024.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.65M, a 6.40% increase from fiscal 2023.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $1.55M, a 267.70% increase from fiscal 2022.
- INVIVYD, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $421.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $459.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $804.00K 10-Q · filed 2026-08-13 | $1.09M derived: sum of 3 quarters · filed 2026-08-13 | $1.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $345.00K 10-Q · filed 2026-05-14 | $631.00K derived: sum of 2 quarters · filed 2026-05-14 | $913.00K derived: sum of 3 quarters · filed 2026-05-14 | $1.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $286.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $568.00K derived: sum of 2 quarters · filed 2026-03-05 | $920.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.35M 10-K · filed 2026-03-05 |
| 2025-09-30 | $282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $634.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.07M 10-Q · filed 2025-11-06 | $1.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $352.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $784.00K 10-Q · filed 2026-08-13 | $1.22M derived: sum of 3 quarters · filed 2026-08-13 | $1.64M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $432.00K 10-Q · filed 2026-05-14 | $864.00K derived: sum of 2 quarters · filed 2026-05-14 | $1.29M derived: sum of 3 quarters · filed 2026-05-14 | $1.68M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $432.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $859.00K derived: sum of 2 quarters · filed 2026-03-05 | $1.25M derived: sum of 3 quarters · filed 2026-03-05 | $1.65M 10-K · filed 2026-03-05 |
| 2024-09-30 | $427.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $813.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.22M 10-Q · filed 2025-11-06 | $1.61M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $386.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $788.00K 10-Q · filed 2025-08-14 | $1.18M derived: sum of 3 quarters · filed 2025-08-14 | $1.57M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $402.00K 10-Q · filed 2025-05-15 | $798.00K derived: sum of 2 quarters · filed 2025-05-15 | $1.19M derived: sum of 3 quarters · filed 2025-05-15 | $1.57M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $785.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.17M derived: sum of 3 quarters · filed 2025-03-20 | $1.55M 10-K · filed 2025-03-20 |
| 2023-09-30 | $389.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $773.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.15M 10-Q · filed 2024-11-14 | $1.33M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $384.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $763.00K 10-Q · filed 2024-08-14 | $942.00K derived: sum of 3 quarters · filed 2024-08-14 | $973.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $379.00K 10-Q · filed 2024-05-09 | $558.00K derived: sum of 2 quarters · filed 2024-05-09 | $589.00K derived: sum of 3 quarters · filed 2024-05-09 | $720.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $179.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $210.00K derived: sum of 2 quarters · filed 2024-03-28 | $341.00K derived: sum of 3 quarters · filed 2024-03-28 | $421.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $162.00K derived: sum of 2 quarters · filed 2023-11-09 | $242.00K 10-Q · filed 2023-11-09 | $242.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-06-30 | $131.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $211.00K 10-Q · filed 2023-08-10 | $211.00K derived: sum of 3 quarters · filed 2024-02-09 | $211.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2022-03-31 | $80.00K 10-Q · filed 2023-05-11 | $80.00K derived: sum of 2 quarters · filed 2024-02-09 | $80.00K derived: sum of 3 quarters · filed 2024-02-09 | $80.00K derived: sum of 4 quarters · filed 2024-02-09 |
| 2021-12-31 | $0.00 derived: 8-K 12 month − 10-Q 9 month · filed 2024-02-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-09 | $0.00 derived: sum of 3 quarters · filed 2024-02-09 | $0.00 8-K · filed 2024-02-09 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $0.00 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |